News
2 Jul 2021
Kymos Acquires Germany’s Prolytic
Dorothee Krone, managing director of Prolytic, and Joan Puig de Dou, CEO of Kymos, sign the merger contract for Kymos and Prolytic to become Kymos Group. © Kymos Group
Kymos, a Contract Research Organisation (CRO) and member of CataloniaBio & HealthTech, has bought German company Prolytic GmbH in order to strengthen its activity in the biologics and advanced therapies market. The company previously acquired Italian firm Pharmaprogress in 2016.
Germany: Kymos creates pan-European CRO
Mentioned Companies
Kymos Pharma Services, S.L.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance